Loading…

Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer

Adequate tumor acquisition is essential to identify somatic molecular alterations in non–small-cell lung cancer (NSCLC), such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations. The success and failure rates for tumor genotyping of tissue obtaine...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2013-11, Vol.8 (11), p.1438-1444
Main Authors: Folch, Erik, Yamaguchi, Norihiro, VanderLaan, Paul A., Kocher, Olivier N., Boucher, David H., Goldstein, Michael A., Huberman, Mark S., Kent, Michael S., Gangadharan, Sidharta P., Costa, Daniel B., Majid, Adnan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5196-52bb0a715770cf033638b464a4c2cd97405d25b36f8accf897e8ac8b033b07a13
cites cdi_FETCH-LOGICAL-c5196-52bb0a715770cf033638b464a4c2cd97405d25b36f8accf897e8ac8b033b07a13
container_end_page 1444
container_issue 11
container_start_page 1438
container_title Journal of thoracic oncology
container_volume 8
creator Folch, Erik
Yamaguchi, Norihiro
VanderLaan, Paul A.
Kocher, Olivier N.
Boucher, David H.
Goldstein, Michael A.
Huberman, Mark S.
Kent, Michael S.
Gangadharan, Sidharta P.
Costa, Daniel B.
Majid, Adnan
description Adequate tumor acquisition is essential to identify somatic molecular alterations in non–small-cell lung cancer (NSCLC), such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations. The success and failure rates for tumor genotyping of tissue obtained from fine-needle aspirates of nodal tissue using a convex probe endobronchial ultrasound (CP-EBUS) and other diagnostic modalities in routine NSCLC care have not been described. Clinicopathologic data, tumor genotype success and failure rates were retrospectively compiled and analyzed from 207 patient-tumor samples sent for routine tumor genotype in clinical practice, including 42 patient-tumor samples obtained from hilar or mediastinal lymph nodes using CP-EBUS. The median age of the patients was 65 years, 62.3% were women, 77.8% were white, 26.6% were never smokers, 73.9% had advanced NSCLC, and 84.1% had adenocarcinoma histology. Tumor tissue was obtained from CP-EBUS–derived hilar or mediastinal nodes in 42 cases (20.2% of total). In this latter cohort, the overall success rate for EGFR mutation analysis was 95.2%, for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation 90.5%, and for ALK fluorescence in situ hybridization 90.5%. In the complete 207 tumors, the success rate for EGFR was 92.3%, for KRAS 91.8%, and for ALK 89.9%. The failure rates were not significantly different when comparing CP-EBUS–derived nodal tissue versus all other samples or versus surgical biopsies of mediastinal nodes, but were significantly lower than image-guided percutaneous transthoracic core-needle biopsies. The success rate of multiple tumor genomic analyses techniques for EGFR, KRAS, and ALK gene abnormalities using routine lung cancer tissue samples obtained from hilar or mediastinal lymph nodes by means of CP-EBUS exceeds 90%, and this method of tissue acquisition is not inferior to other specimen types. Tumor genotype techniques are feasible in most CP-EBUS–derived samples and therefore further expansion of routine tumor genotype for the care of patients with NSCLC may be possible using targeted sample acquisition through CP-EBUS.
doi_str_mv 10.1097/JTO.0b013e3182a471a9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443424209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086415321778</els_id><sourcerecordid>1443424209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5196-52bb0a715770cf033638b464a4c2cd97405d25b36f8accf897e8ac8b033b07a13</originalsourceid><addsrcrecordid>eNp9UU1u1DAUjhCIlsINEPKSTYodO4mzQRqNSgENLRKZtWU7L8Tg2KmdtMyOO3AMbsVJ8GgGKrFgYfk96fvT-7LsOcHnBDf1q_ft9TlWmFCghBeS1UQ2D7JTUpZVTijHD48z5hU7yZ7E-AVjVmLGH2cnBSMFrwk7zX6uOrhZpN4h36PNbpwGdOU7QG2QLqrgnR6MtOgKoLOAVnEyQc4Q0TYa9xmtvbuFb-hj8ArQhev8PWNr5yCjX1yHeh_Qh8XOZkoS7TKm9RKcn3fTXqMFPThzsyRR45K5-_X9x6dRWpuvwVq0WfY-0mkIT7NHvbQRnh3_s2z75qJdv80315fv1qtNrkvSVHlZKIVlTcq6xrrHlFaUK1YxyXShu6ZmuOyKUtGq51Lrnjc1pIGrhFS4loSeZS8PulPw-1yzGE3UKYx04JcoCGOUFazATYKyA1QHH2OAXkzBjDLsBMFiX5NINYl_a0q0F0eHRY3Q_SX96eVe987bGUL8apc7CGIAaedBYFIwyhuWF0mXEIxxnh6pEu31gQbpPLcmMaI2kG7XmQB6Fp03_w_2G4XRtoY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1443424209</pqid></control><display><type>article</type><title>Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer</title><source>ScienceDirect Journals</source><creator>Folch, Erik ; Yamaguchi, Norihiro ; VanderLaan, Paul A. ; Kocher, Olivier N. ; Boucher, David H. ; Goldstein, Michael A. ; Huberman, Mark S. ; Kent, Michael S. ; Gangadharan, Sidharta P. ; Costa, Daniel B. ; Majid, Adnan</creator><creatorcontrib>Folch, Erik ; Yamaguchi, Norihiro ; VanderLaan, Paul A. ; Kocher, Olivier N. ; Boucher, David H. ; Goldstein, Michael A. ; Huberman, Mark S. ; Kent, Michael S. ; Gangadharan, Sidharta P. ; Costa, Daniel B. ; Majid, Adnan</creatorcontrib><description>Adequate tumor acquisition is essential to identify somatic molecular alterations in non–small-cell lung cancer (NSCLC), such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations. The success and failure rates for tumor genotyping of tissue obtained from fine-needle aspirates of nodal tissue using a convex probe endobronchial ultrasound (CP-EBUS) and other diagnostic modalities in routine NSCLC care have not been described. Clinicopathologic data, tumor genotype success and failure rates were retrospectively compiled and analyzed from 207 patient-tumor samples sent for routine tumor genotype in clinical practice, including 42 patient-tumor samples obtained from hilar or mediastinal lymph nodes using CP-EBUS. The median age of the patients was 65 years, 62.3% were women, 77.8% were white, 26.6% were never smokers, 73.9% had advanced NSCLC, and 84.1% had adenocarcinoma histology. Tumor tissue was obtained from CP-EBUS–derived hilar or mediastinal nodes in 42 cases (20.2% of total). In this latter cohort, the overall success rate for EGFR mutation analysis was 95.2%, for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation 90.5%, and for ALK fluorescence in situ hybridization 90.5%. In the complete 207 tumors, the success rate for EGFR was 92.3%, for KRAS 91.8%, and for ALK 89.9%. The failure rates were not significantly different when comparing CP-EBUS–derived nodal tissue versus all other samples or versus surgical biopsies of mediastinal nodes, but were significantly lower than image-guided percutaneous transthoracic core-needle biopsies. The success rate of multiple tumor genomic analyses techniques for EGFR, KRAS, and ALK gene abnormalities using routine lung cancer tissue samples obtained from hilar or mediastinal lymph nodes by means of CP-EBUS exceeds 90%, and this method of tissue acquisition is not inferior to other specimen types. Tumor genotype techniques are feasible in most CP-EBUS–derived samples and therefore further expansion of routine tumor genotype for the care of patients with NSCLC may be possible using targeted sample acquisition through CP-EBUS.</description><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1097/JTO.0b013e3182a471a9</identifier><identifier>PMID: 24128714</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - diagnosis ; Adenocarcinoma - genetics ; Adult ; Aged ; Aged, 80 and over ; Anaplastic lymphoma kinase ; Biopsy, Fine-Needle ; Bone specimen ; Bronchi - diagnostic imaging ; Bronchi - metabolism ; Bronchi - pathology ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Squamous Cell - diagnosis ; Carcinoma, Squamous Cell - genetics ; Computed tomography ; Core biopsy ; Endobronchial ultrasound ; Endosonography ; Epidermal growth factor receptor ; Failure ; Female ; Follow-Up Studies ; Genotype ; Humans ; Kirsten rat sarcoma viral oncogene homolog ; Lung cancer ; Lung Neoplasms - diagnosis ; Lung Neoplasms - genetics ; Lymph Nodes - diagnostic imaging ; Lymph Nodes - metabolism ; Lymph Nodes - pathology ; Male ; Mediastinoscopy ; Middle Aged ; Molecular testing ; Mutation - genetics ; Neoplasm Staging ; Never smokers ; Non–small-cell lung cancer ; Polymerase Chain Reaction ; Prognosis ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Receptor, Epidermal Growth Factor - genetics ; Retrospective Studies ; Transbronchial needle aspiration ; Tumor genotype</subject><ispartof>Journal of thoracic oncology, 2013-11, Vol.8 (11), p.1438-1444</ispartof><rights>2013 International Association for the Study of Lung Cancer</rights><rights>Copyright © 2013 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5196-52bb0a715770cf033638b464a4c2cd97405d25b36f8accf897e8ac8b033b07a13</citedby><cites>FETCH-LOGICAL-c5196-52bb0a715770cf033638b464a4c2cd97405d25b36f8accf897e8ac8b033b07a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1556086415321778$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3547,27923,27924,45779</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24128714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Folch, Erik</creatorcontrib><creatorcontrib>Yamaguchi, Norihiro</creatorcontrib><creatorcontrib>VanderLaan, Paul A.</creatorcontrib><creatorcontrib>Kocher, Olivier N.</creatorcontrib><creatorcontrib>Boucher, David H.</creatorcontrib><creatorcontrib>Goldstein, Michael A.</creatorcontrib><creatorcontrib>Huberman, Mark S.</creatorcontrib><creatorcontrib>Kent, Michael S.</creatorcontrib><creatorcontrib>Gangadharan, Sidharta P.</creatorcontrib><creatorcontrib>Costa, Daniel B.</creatorcontrib><creatorcontrib>Majid, Adnan</creatorcontrib><title>Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer</title><title>Journal of thoracic oncology</title><addtitle>J Thorac Oncol</addtitle><description>Adequate tumor acquisition is essential to identify somatic molecular alterations in non–small-cell lung cancer (NSCLC), such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations. The success and failure rates for tumor genotyping of tissue obtained from fine-needle aspirates of nodal tissue using a convex probe endobronchial ultrasound (CP-EBUS) and other diagnostic modalities in routine NSCLC care have not been described. Clinicopathologic data, tumor genotype success and failure rates were retrospectively compiled and analyzed from 207 patient-tumor samples sent for routine tumor genotype in clinical practice, including 42 patient-tumor samples obtained from hilar or mediastinal lymph nodes using CP-EBUS. The median age of the patients was 65 years, 62.3% were women, 77.8% were white, 26.6% were never smokers, 73.9% had advanced NSCLC, and 84.1% had adenocarcinoma histology. Tumor tissue was obtained from CP-EBUS–derived hilar or mediastinal nodes in 42 cases (20.2% of total). In this latter cohort, the overall success rate for EGFR mutation analysis was 95.2%, for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation 90.5%, and for ALK fluorescence in situ hybridization 90.5%. In the complete 207 tumors, the success rate for EGFR was 92.3%, for KRAS 91.8%, and for ALK 89.9%. The failure rates were not significantly different when comparing CP-EBUS–derived nodal tissue versus all other samples or versus surgical biopsies of mediastinal nodes, but were significantly lower than image-guided percutaneous transthoracic core-needle biopsies. The success rate of multiple tumor genomic analyses techniques for EGFR, KRAS, and ALK gene abnormalities using routine lung cancer tissue samples obtained from hilar or mediastinal lymph nodes by means of CP-EBUS exceeds 90%, and this method of tissue acquisition is not inferior to other specimen types. Tumor genotype techniques are feasible in most CP-EBUS–derived samples and therefore further expansion of routine tumor genotype for the care of patients with NSCLC may be possible using targeted sample acquisition through CP-EBUS.</description><subject>Adenocarcinoma - diagnosis</subject><subject>Adenocarcinoma - genetics</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anaplastic lymphoma kinase</subject><subject>Biopsy, Fine-Needle</subject><subject>Bone specimen</subject><subject>Bronchi - diagnostic imaging</subject><subject>Bronchi - metabolism</subject><subject>Bronchi - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Squamous Cell - diagnosis</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Computed tomography</subject><subject>Core biopsy</subject><subject>Endobronchial ultrasound</subject><subject>Endosonography</subject><subject>Epidermal growth factor receptor</subject><subject>Failure</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Genotype</subject><subject>Humans</subject><subject>Kirsten rat sarcoma viral oncogene homolog</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - genetics</subject><subject>Lymph Nodes - diagnostic imaging</subject><subject>Lymph Nodes - metabolism</subject><subject>Lymph Nodes - pathology</subject><subject>Male</subject><subject>Mediastinoscopy</subject><subject>Middle Aged</subject><subject>Molecular testing</subject><subject>Mutation - genetics</subject><subject>Neoplasm Staging</subject><subject>Never smokers</subject><subject>Non–small-cell lung cancer</subject><subject>Polymerase Chain Reaction</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins - genetics</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Retrospective Studies</subject><subject>Transbronchial needle aspiration</subject><subject>Tumor genotype</subject><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9UU1u1DAUjhCIlsINEPKSTYodO4mzQRqNSgENLRKZtWU7L8Tg2KmdtMyOO3AMbsVJ8GgGKrFgYfk96fvT-7LsOcHnBDf1q_ft9TlWmFCghBeS1UQ2D7JTUpZVTijHD48z5hU7yZ7E-AVjVmLGH2cnBSMFrwk7zX6uOrhZpN4h36PNbpwGdOU7QG2QLqrgnR6MtOgKoLOAVnEyQc4Q0TYa9xmtvbuFb-hj8ArQhev8PWNr5yCjX1yHeh_Qh8XOZkoS7TKm9RKcn3fTXqMFPThzsyRR45K5-_X9x6dRWpuvwVq0WfY-0mkIT7NHvbQRnh3_s2z75qJdv80315fv1qtNrkvSVHlZKIVlTcq6xrrHlFaUK1YxyXShu6ZmuOyKUtGq51Lrnjc1pIGrhFS4loSeZS8PulPw-1yzGE3UKYx04JcoCGOUFazATYKyA1QHH2OAXkzBjDLsBMFiX5NINYl_a0q0F0eHRY3Q_SX96eVe987bGUL8apc7CGIAaedBYFIwyhuWF0mXEIxxnh6pEu31gQbpPLcmMaI2kG7XmQB6Fp03_w_2G4XRtoY</recordid><startdate>201311</startdate><enddate>201311</enddate><creator>Folch, Erik</creator><creator>Yamaguchi, Norihiro</creator><creator>VanderLaan, Paul A.</creator><creator>Kocher, Olivier N.</creator><creator>Boucher, David H.</creator><creator>Goldstein, Michael A.</creator><creator>Huberman, Mark S.</creator><creator>Kent, Michael S.</creator><creator>Gangadharan, Sidharta P.</creator><creator>Costa, Daniel B.</creator><creator>Majid, Adnan</creator><general>Elsevier Inc</general><general>Copyright by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201311</creationdate><title>Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer</title><author>Folch, Erik ; Yamaguchi, Norihiro ; VanderLaan, Paul A. ; Kocher, Olivier N. ; Boucher, David H. ; Goldstein, Michael A. ; Huberman, Mark S. ; Kent, Michael S. ; Gangadharan, Sidharta P. ; Costa, Daniel B. ; Majid, Adnan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5196-52bb0a715770cf033638b464a4c2cd97405d25b36f8accf897e8ac8b033b07a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma - diagnosis</topic><topic>Adenocarcinoma - genetics</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anaplastic lymphoma kinase</topic><topic>Biopsy, Fine-Needle</topic><topic>Bone specimen</topic><topic>Bronchi - diagnostic imaging</topic><topic>Bronchi - metabolism</topic><topic>Bronchi - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Squamous Cell - diagnosis</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Computed tomography</topic><topic>Core biopsy</topic><topic>Endobronchial ultrasound</topic><topic>Endosonography</topic><topic>Epidermal growth factor receptor</topic><topic>Failure</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Genotype</topic><topic>Humans</topic><topic>Kirsten rat sarcoma viral oncogene homolog</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - genetics</topic><topic>Lymph Nodes - diagnostic imaging</topic><topic>Lymph Nodes - metabolism</topic><topic>Lymph Nodes - pathology</topic><topic>Male</topic><topic>Mediastinoscopy</topic><topic>Middle Aged</topic><topic>Molecular testing</topic><topic>Mutation - genetics</topic><topic>Neoplasm Staging</topic><topic>Never smokers</topic><topic>Non–small-cell lung cancer</topic><topic>Polymerase Chain Reaction</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins - genetics</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Retrospective Studies</topic><topic>Transbronchial needle aspiration</topic><topic>Tumor genotype</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Folch, Erik</creatorcontrib><creatorcontrib>Yamaguchi, Norihiro</creatorcontrib><creatorcontrib>VanderLaan, Paul A.</creatorcontrib><creatorcontrib>Kocher, Olivier N.</creatorcontrib><creatorcontrib>Boucher, David H.</creatorcontrib><creatorcontrib>Goldstein, Michael A.</creatorcontrib><creatorcontrib>Huberman, Mark S.</creatorcontrib><creatorcontrib>Kent, Michael S.</creatorcontrib><creatorcontrib>Gangadharan, Sidharta P.</creatorcontrib><creatorcontrib>Costa, Daniel B.</creatorcontrib><creatorcontrib>Majid, Adnan</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Folch, Erik</au><au>Yamaguchi, Norihiro</au><au>VanderLaan, Paul A.</au><au>Kocher, Olivier N.</au><au>Boucher, David H.</au><au>Goldstein, Michael A.</au><au>Huberman, Mark S.</au><au>Kent, Michael S.</au><au>Gangadharan, Sidharta P.</au><au>Costa, Daniel B.</au><au>Majid, Adnan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer</atitle><jtitle>Journal of thoracic oncology</jtitle><addtitle>J Thorac Oncol</addtitle><date>2013-11</date><risdate>2013</risdate><volume>8</volume><issue>11</issue><spage>1438</spage><epage>1444</epage><pages>1438-1444</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><abstract>Adequate tumor acquisition is essential to identify somatic molecular alterations in non–small-cell lung cancer (NSCLC), such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations. The success and failure rates for tumor genotyping of tissue obtained from fine-needle aspirates of nodal tissue using a convex probe endobronchial ultrasound (CP-EBUS) and other diagnostic modalities in routine NSCLC care have not been described. Clinicopathologic data, tumor genotype success and failure rates were retrospectively compiled and analyzed from 207 patient-tumor samples sent for routine tumor genotype in clinical practice, including 42 patient-tumor samples obtained from hilar or mediastinal lymph nodes using CP-EBUS. The median age of the patients was 65 years, 62.3% were women, 77.8% were white, 26.6% were never smokers, 73.9% had advanced NSCLC, and 84.1% had adenocarcinoma histology. Tumor tissue was obtained from CP-EBUS–derived hilar or mediastinal nodes in 42 cases (20.2% of total). In this latter cohort, the overall success rate for EGFR mutation analysis was 95.2%, for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation 90.5%, and for ALK fluorescence in situ hybridization 90.5%. In the complete 207 tumors, the success rate for EGFR was 92.3%, for KRAS 91.8%, and for ALK 89.9%. The failure rates were not significantly different when comparing CP-EBUS–derived nodal tissue versus all other samples or versus surgical biopsies of mediastinal nodes, but were significantly lower than image-guided percutaneous transthoracic core-needle biopsies. The success rate of multiple tumor genomic analyses techniques for EGFR, KRAS, and ALK gene abnormalities using routine lung cancer tissue samples obtained from hilar or mediastinal lymph nodes by means of CP-EBUS exceeds 90%, and this method of tissue acquisition is not inferior to other specimen types. Tumor genotype techniques are feasible in most CP-EBUS–derived samples and therefore further expansion of routine tumor genotype for the care of patients with NSCLC may be possible using targeted sample acquisition through CP-EBUS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24128714</pmid><doi>10.1097/JTO.0b013e3182a471a9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1556-0864
ispartof Journal of thoracic oncology, 2013-11, Vol.8 (11), p.1438-1444
issn 1556-0864
1556-1380
language eng
recordid cdi_proquest_miscellaneous_1443424209
source ScienceDirect Journals
subjects Adenocarcinoma - diagnosis
Adenocarcinoma - genetics
Adult
Aged
Aged, 80 and over
Anaplastic lymphoma kinase
Biopsy, Fine-Needle
Bone specimen
Bronchi - diagnostic imaging
Bronchi - metabolism
Bronchi - pathology
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Squamous Cell - diagnosis
Carcinoma, Squamous Cell - genetics
Computed tomography
Core biopsy
Endobronchial ultrasound
Endosonography
Epidermal growth factor receptor
Failure
Female
Follow-Up Studies
Genotype
Humans
Kirsten rat sarcoma viral oncogene homolog
Lung cancer
Lung Neoplasms - diagnosis
Lung Neoplasms - genetics
Lymph Nodes - diagnostic imaging
Lymph Nodes - metabolism
Lymph Nodes - pathology
Male
Mediastinoscopy
Middle Aged
Molecular testing
Mutation - genetics
Neoplasm Staging
Never smokers
Non–small-cell lung cancer
Polymerase Chain Reaction
Prognosis
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins p21(ras)
ras Proteins - genetics
Receptor, Epidermal Growth Factor - genetics
Retrospective Studies
Transbronchial needle aspiration
Tumor genotype
title Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T23%3A18%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adequacy%20of%20Lymph%20Node%20Transbronchial%20Needle%20Aspirates%20Using%20Convex%20Probe%20Endobronchial%20Ultrasound%20for%20Multiple%20Tumor%20Genotyping%20Techniques%20in%20Non%E2%80%93Small-Cell%20Lung%20Cancer&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Folch,%20Erik&rft.date=2013-11&rft.volume=8&rft.issue=11&rft.spage=1438&rft.epage=1444&rft.pages=1438-1444&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1097/JTO.0b013e3182a471a9&rft_dat=%3Cproquest_cross%3E1443424209%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5196-52bb0a715770cf033638b464a4c2cd97405d25b36f8accf897e8ac8b033b07a13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1443424209&rft_id=info:pmid/24128714&rfr_iscdi=true